News round-up Monday, April 14

announces successful completion of Phase I study with SOL-116. Read more.

OncoZenge receives milestone compensation from Molteni. Read moreThe company also enters into a licensing agreement with Avernus Pharma for BupiZenge in the GCC region. Read more.

UsDsign announces that a new preclinical study comparing the bone formation potential of various calcium phosphate-based synthetic bone graft substitutes containing silicate has been published in the Journal of Orthopaedic Surgery and Research. Read more.

Micropos Medical announces that the new share issue was fully subscribed. Read more.

Products from S2Medical in advanced wound healing procured by Skåne Region. Read more.

Lumito launches new website and focuses on increased objectivity in tissue analysis. Read more.

AroCells The board of directors proposes to the annual general meeting that the parent company change its name to IDL Diagnostics. Read more.

SciBase launches the next generation Nevisense. Read more.

Nykode Therapeutics publishes financial calendar. Read more.

MucoLife Therapeutics appoints Dr. Maarten Kraan to the board to accelerate the development of first-of-its-kind mucus-modulating therapies. Read more.

Guard Therapeutics announces changes in the number of shares and votes. Read more.

Quia Pharma announces shareholders' proposals for new board members ahead of the extraordinary general meeting. Read more.

Terveystalo informs about personnel changes. Read more.

Amendment: Ortivus The board of directors withdraws the proposal to the annual general meeting on May 8, 2025 regarding authorization for the board of directors to issue shares, etc. Read more.

Raytelligences CEO Ben Hedenberg has passed away. Read more.